Researchers developed BOUQUET, an algorithm using machine learning, to create 3D maps that reveal factors essential to gene expression. Learn more about how these findings advance understanding of cell identity and disease mechanisms: https://ow.ly/AtSv50Yri93
St. Jude scientists and collaborators identified the likely cell of origin for pineoblastoma and uncovered a shared molecular dependency across multiple pediatric brain tumors. These findings point to a new therapeutic vulnerability that should be explored. https://ow.ly/IWXm50YpKAR
🎧 Our March podcast: We talk to Dylan Graetz and Erica Kaye
@stjuderesearch.bsky.social about qualitative research in oncology
thelancet.com/multimedia/p...
Follow In Conversation With
Spotify: open.spotify.com/show/3JOj0Cl...
Apple: podcasts.apple.com/us/podcast/t...
Researchers show that plasma microbial cell-free DNA sequencing can predict bloodstream infections in children with leukemia days before symptoms appear. Early prediction could allow timely intervention and improve outcomes for immunocompromised children. https://ow.ly/sUbu50Yo4xh
Through the Pediatric Translational Neuroscience Initiative, researchers are driving progress in disorders including rare epilepsies and spinal muscular atrophy (SMA), from patient-derived models to the first in utero treatment of SMA.
Today is Rare Disease Day, a reminder that “rare” can still have a big impact. At St. Jude, advancing care for rare and ultra-rare pediatric conditions, including neurological disease, is core to our mission.
Diego Hijano, MD, MSc, said, “There’s a difference between reading about vaccine safety in a journal and hearing from someone you know and trust.” Sharing personal experience can help build trust and support informed vaccine decisions.
Respiratory viruses continue to circulate, and conversations about vaccines remain both timely and personal. At St. Jude, science and patient care often intersect with the same questions families face every day.
New research shows infants’ immune systems respond differently to respiratory syncytial virus (RSV) and SARS-CoV-2. The study provides a blueprint for better understanding infant immunity. https://ow.ly/qLfs50Ym5Os
Researchers at St. Jude are mapping cell fate decisions, motor function wiring and disease-linked gene regulation to better understand developing neural systems and how neurologic diseases disrupt those processes. https://ow.ly/Q6C850Ym19v
St. Jude scientists found that hearing loss as a side effect of radiation therapy can increase the risk of cognitive decline. https://ow.ly/zYyV50Ykvu1
St. Jude announces that James R. Downing, MD, will step down as president and CEO this year as part of a planned leadership transition. He will continue to serve the mission in a faculty role within Global Pediatric Medicine. ow.ly/fLiy50Yibmz
“The informatics will need to grow to classify the full scope of cancer types diagnosed in children, but we’ve developed something quite powerful that is likely to be more broadly adopted in the community,” said Paul Northcott, PhD.
St. Jude researchers and collaborators developed M-PACT, a tool that leverages AI to classify pediatric brain tumors using cell free DNA from cerebrospinal fluid. The approach could improve diagnosis and disease monitoring when tissue biopsy is not feasible. ow.ly/aUcU50Yh2bb
We are honored to be ranked second by @forbes.com as one of America’s Best Large Employers 2026. The distinction reflects employee feedback on workplace culture, benefits and opportunities for advancement at St. Jude. ow.ly/Lbqb50Ycz1C
Learn more about how St. Jude is helping childhood cancer go from invisible to a public health priority. ow.ly/11hr50Y8sZk
#WorldCancerDay
Ecuador is advancing treatment systems, improving access to essential medicines and preparing a childhood cancer registry to guide future care. These steps reflect the spirit of our institution, founded on this day in 1962, to bring research and care to the world’s children.
On World Cancer Day, St. Jude recognizes the progress taking shape through the Global Platform for Access to Childhood Cancer Medicines. The initiative, developed with @who.int, supports efforts to build consistent, evidence-based care for children with cancer.
Topics include cancer genomics, CAR-T, epigenetics, survivorship and more. The series is virtual and registration is free!
Sign up today: ow.ly/5PyF50Y569F
The 12th season of The Science of Childhood Cancer begins February 5th. For the next 15 weeks, leading experts across the spectrum of pediatric cancer research will give lectures on Thursdays at 12pm ET / 1 pm CT.
When we design therapies specifically for children, we not only improve their chances; we often uncover insights that help adults too,” said Charles Roberts, MD, PhD, St. Jude Comprehensive Cancer Center director.
Childhood cancers are biologically distinct from adult cancers. These diseases often form because normal developmental processes go wrong, which means adult treatments do not work the same in children. See how research at St. Jude is reshaping this landscape: ow.ly/sZWL50Y4xoH
“There’s a prediction element, but it’s a prediction with a huge amount of data behind it,” said Richard Webby, PhD. Even when the flu vaccine is not a perfect match for the circulating strains of the virus, it remains a critical tool, particularly for the immunocompromised.
Infectious diseases remain one of the greatest threats to children. As a WHO Collaborating Center for Influenza, St. Jude helps inform global flu vaccine decisions through year-round surveillance and data sharing.
St. Jude congratulates Shannon McKinney-Freeman, PhD, on being named the 2025 Postdoctoral Association Mentor of the Year. Nominated by four mentees, McKinney-Freeman is recognized for her dedication to advancing the next generation of scientists.
#MentoringMonth
Recent findings from the IMPAACT Network study show adolescents with HIV in five countries safely switched from daily oral meds to all-injectable treatment every 2 months, maintaining viral suppression. 100% of patients in the trial preferred injectables. ow.ly/nUQQ50XXvQl
Join our webinar on Feb 4, Improving Outcomes for Children with Serious Illness through Applied Qualitative Research
Hosted by @stjuderesearch.bsky.social in collaboration with @thelancetoncol.bsky.social and @thelancethaem.bsky.social
🖱️Register here: stjudeglobal.zoom.us/meeting/regi...
For decades, the mystery of how DICER1 mutations promote pediatric rhabdomyosarcoma remained unsolved. Mark Hatley, MD, PhD, and his lab cracked the case, powered by advancements in single-cell RNA sequencing, revealing new paths for intervention. https://ow.ly/UiCG50XU294
Scientists discovered cancer cells use interactive LINE-1 retrotransposon regions to reshape 3D genome architecture, enhancing oncogenic gene expression. This mechanism links LINE-1 activity to cancer development & highlights potential therapeutic targets. ow.ly/qVN650XS0MN
2025 brought new milestones in research, care, education and global partnership at St. Jude. This year’s achievements set the stage for new advances in 2026 and beyond as we continue working to improve the lives of children everywhere.
#HappyNewYear #StJude
